Helicobacter pylori infection has been indicated as the main pathogenic factor in the development of chronic gastritis, peptic ulcer disease, and gastric malignancies. Although the vast majority of infected subjects do not carry but a mild, asymptomatic gastritis, still there are some cases in which the eradication of the infection appears mandatory. This review addresses current anti-Helicobacter regimens and pharmacological resources, and highlights the pros and cons of each of them, according to the most recent and reliable clinical trials. Also, basic recommendations are given, regarding treatment choice in the event of the failure of a first or second line eradicating strategy, and about the implementation of standard regimens with newer antibacterial devices as probiotics. PMID: 15720247 [PubMed - indexed for MEDLINE]
Candelli, M., Nista, E. C., Carloni, E., Pignataro, G., Zocco, M. A., Cazzato, I. A., Di Campli, C., Fini, L., Gasbarrini, G. B., Gasbarrini, A., Treatment of H. pylori infection: a review., <<CURRENT MEDICINAL CHEMISTRY>>, 2005; (12(4)): 375-384 [http://hdl.handle.net/10807/21013]
Treatment of H. pylori infection: a review.
Candelli, Marcello;Nista, Enrico Celestino;Carloni, Emilia;Pignataro, Giulia;Zocco, Maria Assunta;Cazzato, Immacolata Alessia;Di Campli, Cristiana;Fini, Lucia;Gasbarrini, Giovanni Battista;Gasbarrini, Antonio
2005
Abstract
Helicobacter pylori infection has been indicated as the main pathogenic factor in the development of chronic gastritis, peptic ulcer disease, and gastric malignancies. Although the vast majority of infected subjects do not carry but a mild, asymptomatic gastritis, still there are some cases in which the eradication of the infection appears mandatory. This review addresses current anti-Helicobacter regimens and pharmacological resources, and highlights the pros and cons of each of them, according to the most recent and reliable clinical trials. Also, basic recommendations are given, regarding treatment choice in the event of the failure of a first or second line eradicating strategy, and about the implementation of standard regimens with newer antibacterial devices as probiotics. PMID: 15720247 [PubMed - indexed for MEDLINE]
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
